Newsletter | August 21, 2019

08.21.19 -- Biologics Dose And API Outsourcing: A Decade Of Decline?

 
From The Editor
Biologics Dose And API Outsourcing: A Decade Of Decline?
 
By Louis Garguilo, Chief Editor, Outsourced Pharma

Can it be that today, when we expect increasing demand for CDMO services, biopharmaceutical companies have decided to outsource less of their commercial production needs than in the past? Some new data provided exclusively to Outsourced Pharma by PharmSource, an organization of GlobalData Plc., seems to suggest so. But if so, why that apparent trend reversal? 

Featured Editorial
Private Equity Accelerating Consolidation In The CDMO Market
 
By Bill Bolding and Ajeya Shekar, Provident Healthcare Partners

The CDMO industry has benefitted from Big Pharma’s divestment of in-house development and manufacturing capabilities in this current economic cycle. The rise of competition from new CDMO players and consolidation within the pharmaceutical sponsor space, however, has led to a crowded market and, in many cases, a commoditized service base.

4 (More) Microbiological Root Cause Analyses Lessons From Sherlock Holmes
By Paula Peacos, ValSource, Inc.

Bias can take many forms and is often not easily recognized by an investigator. Sherlock Holmes was keenly aware of bias's potential impacts. Applying more of Holmes’s famous observations and investigative principles can uncover hidden bias and greatly increase an investigator’s chance of finding that elusive definitive root cause.

Industry Insights
3 Steps To Strengthen Your Supply Chain Partnerships
Article | By Travis Hudson, Singota Solutions

If you’re struggling to achieve legitimate value, take advantage of this three-step process to strengthen your supply chain partnerships.

Amgen’s Digital Transformation: Link Suppliers' Raw Material Data To Patients
Article | By Cenk Undey, Amgen

Using its Supplier Relationship Excellence program, Amgen opened the lines of communication with suppliers and created a feedback loop where data can be shared to optimize operational performance. 

Is Your Sterile Injectable Ready For Changes In Raw Materials?
Article | By Lisa Cherry, Ph.D., Pfizer CentreOne Contract Manufacturing

Over the life of a drug, changes in raw materials are inevitable. But even a small modification can throw your drug out of compliance. Learn how to safeguard drug integrity when raw materials change.

Challenges, Risks, And Strategies For Biologic Substance Manufacturing
Article | Thermo Fisher Scientific

From discussions with pharmaceutical and biotechnology industry leaders it is clear that demand forecasting is a significant challenge when planning biologic drug substance production.

Drug Safety And Product Protection Driving Blister Packaging Growth
White Paper | Ropack Pharma Solutions

Trends in the packaging of prescription and over-the-counter drugs indicate continued growth in the blister packaging market. 

Contribute To Outsourced Pharma
Article Submission Guidelines
 

Think you have a good idea for an article that Outsourced Pharma readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director. 

Life Science Leader Magazine
 

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.

Connect With Outsourced Pharma:
   LinkedIn